Search clinical trials for: Daclatasvir dihydrochloride

Total 7418 results

Assiut University

Unknown

The Effect of Direct Antiviral Therapy on Hepatitis c Virus-related Thrombocytopenia

Hepatitis C

Egypt
Getz Pharma

Completed

Direct Acting Anti-Viral's In Chronic HCV Patients

Safety Issues

Pakistan
Bristol-Myers Squibb

Withdrawn

A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3

Hepatitis C

France, Canada
Kirby Institute
Bristol-Myers Squibb

Withdrawn

Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism (HEPCOG-II)

Hepatitis C, Chronic

Australia
Tehran University of Medical Sciences
RojanPharma Pharmaceutical Company

Completed

Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus (HIV200)

Human Immunodeficiency Virus | Hepatitis C Virus Infection, Response to Therapy of

Iran, Islamic Republic of
Postgraduate Institute of Medical Education and...
Directorate of Health and Family Welfare, Punjab

Unknown

Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model

Chronic Hepatitis c

India
Bristol-Myers Squibb

No longer available

EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C

Chronic Hepatitis C

Netherlands, Austria, Germany, United Kingdom, Sweden
Assiut University

Not yet recruiting

the Pulmonary Safety of Antihepatitis C Treatment

Hepatitis C
Ain Shams University
Cairo University

Recruiting

Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children

HCV

Egypt
Tainan Municipal Hospital

Withdrawn

Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas

Hepatitis c
Eman Sayed Hassan Abd Allah

Unknown

Hepatitis c and Vitamin D and Iron Status (hepatitisc)

Hepatitis C
Assiut University

Unknown

Effect of Direct AntiViral Drugs of Chronic HCV on eGFR in Assuit Universiry Hospital

Antiviral Drug
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 (PRINCIPAL)

Hepatitis C Virus (HCV)

Australia, Belgium, France, Italy, Japan, Korea, Republic of, Mexico, Russian Federation, Taiwan, United States, Chile, Hong Kong, Argentina, Netherlands, United Kingdom, Singapore, New Zealand, Finland, Greece
MTI University

Unknown

Study of the Early Occurrence of Hepatocellular Carcinoma (HCC) in Egyptian HCV Infected Patients Receiving Sofosbuvir and Daclatasvir

Hepatitis C

Egypt
Bristol-Myers Squibb

Completed

Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual

Hepatitis C

China, Korea, Republic of, Taiwan
Bristol-Myers Squibb

Completed

Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial

Hepatitis C

United States, Australia, France, Japan, Spain, Sweden, Canada, Germany, Mexico, Denmark, Italy, Korea, Republic of, Taiwan, Argentina, Brazil, Ireland, Poland, Puerto Rico, United Kingdom
Tarek I. Hassanein, M.D., FACP, FAG, AGAF

Completed

Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics

Hepatitis C | Cirrhosis

United States
Bristol-Myers Squibb
Pharmasset

Completed

Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

Chronic Hepatitis C

United States, Puerto Rico
Janssen R&D Ireland

Withdrawn

An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.

Renal Impairment | End-stage Renal Disease

France, Spain
ANRS, Emerging Infectious Diseases
Bristol-Myers Squibb

Withdrawn

Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen (QUATTROTURBO)

Hepatitis C Virus Genotype 4 Infection

France
Sherief Abd-Elsalam
Benha University

Unknown

Effect of Direct-acting Antiviral Drugs on Erectile Function

Hepatitis C

Egypt
Bristol-Myers Squibb

Completed

A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients

Hepatitis C

Japan
Third Affiliated Hospital, Sun Yat-Sen University

Completed

The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAs

Chronic Hepatitis C
Ain Shams University

Unknown

Metabolic Changes in Chronic HCV Patients Receiving DAAS (HCV DAAS)

Chronic Hepatitis C

Egypt
Kaohsiung Medical University Chung-Ho Memorial...
National Taiwan University Hospital; China Medical University Hospital; Chang... and other collaborators

Completed

Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV

Hepatitis C

Taiwan
Third Affiliated Hospital, Sun Yat-Sen University

Completed

Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAs

Chronic Hepatitis C (Disorder)
Bristol-Myers Squibb
Janssen Research & Development, LLC

Completed

Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus

Hepatitis C Virus

Argentina, France, United States, Spain, Germany, Hungary
Galderma R&D

Completed

Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma

Basal Cell Carcinoma

Australia
Bristol-Myers Squibb

Completed

A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects

Hepatitis C Virus Infection

Japan
Bayer

Completed

A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases (ALSYMPCA)

Bone Metastases | Hormone Refractory Prostate Cancer

Italy, Spain, Hong Kong, Canada, United Kingdom, France, Australia, United States, Germany, Brazil, Israel, Netherlands, Norway, Belgium, Sweden, Czech Republic, Poland, Singapore, Slovakia
Bristol-Myers Squibb

Completed

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)

Hepatitis C Infection

Japan
Bristol-Myers Squibb

Withdrawn

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

Hepatitis C Virus

United States
Benha University

Completed

Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters

Male Infertility | HCV

Egypt
National Cancer Institute (NCI)

Active, not recruiting

Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal Large B-Cell Lymphoma | Refractory Primary Mediastinal Large B-Cell Lymphoma

United States
Bristol-Myers Squibb

Completed

Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia (MAGNITUDE)

Hepatitis C Virus

Australia, France, United States, Spain, Italy, Netherlands, Romania, Russian Federation
Federal University of São Paulo

Completed

Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)

Hepatitis C, Chronic

Brazil
Janssen Research & Development, LLC

Completed

An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease

Hepatitis C, Chronic

United States
Bristol-Myers Squibb

Completed

Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant (ALLY 1)

Hepatitis C

United States
Bristol-Myers Squibb

Completed

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)

Hepatitis C Infection

United States, France
Cairo University

Unknown

Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19

COVID-19
Beni-Suef University

Completed

Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4

Chronic Hepatitis C Virus Infection
Janssen Research & Development, LLC

Completed

Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection (ACCORDION-1)

Hepatitis C Virus

United States, Canada
Bristol-Myers Squibb

Completed

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin (D-LITE)

Hepatitis C

United States
Bristol-Myers Squibb

Completed

To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet

Hepatitis C

United States
Azienda Ospedaliera Città della Salute e della...

Recruiting

Analysis of the Effectiveness of the Use of Glycine Powder and Angled Implant Brush in Oral Hygiene Maintenance in Patients Reinstated With Columbus Bridge ProtocolTM

Plaque, Dental

Italy
Bristol-Myers Squibb

Completed

Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection (COMMAND-3)

Hepatitis C

Australia, France, Germany, Italy, United Kingdom, United States, Canada, Poland, Austria, Denmark, Israel, Spain, Russian Federation, Switzerland, Argentina, Brazil
Daiichi Sankyo, Inc.

No longer available

Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib

Acute Myeloid Leukemia With Gene Mutations
Providence VA Medical Center
BioMarin Pharmaceutical; Lifespan

Completed

Rhode Island Diastolic Dysfunction - Heart Failure (RIDD-HF)

Heart Failure | Cardiovascular Disease

United States
AbbVie

Completed

A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection (ENDURANCE-3)

Chronic Hepatitis C | Hepatitis C Virus | Genotype 3 Hepatitis C Virus
Zagazig University
Cairo University

Unknown

Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4

Hepatitis C

3

Subscribe